Literature DB >> 17712798

Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells.

Martin D Forster1, Michael G Ormerod, Roshan Agarwal, Stanley B Kaye, Ann L Jackman.   

Abstract

The alpha-folate receptor (alpha-FR) is a folate transporter with restricted expression levels in normal tissues. It is over-expressed in several cancers, particularly epithelial carcinomas, including nonmucinous ovarian carcinoma. It offers a novel therapeutic target for selective imaging and cytotoxic agents. Measurement of the receptor could be a valuable tool in selecting patients more likely to respond to new drugs that target the alpha-FR, and monitoring them while on treatment. While tumor samples are often unavailable, a number of patients who relapse develop ascites, which are often rich in tumor cells. We have therefore developed a triple antibody flow cytometric method to assess alpha-FR expression on tumor cells from ascites. An antibody to BerEP4, an epithelial cell marker expressed on >90% ovarian cancers, labeled with fluorescein, and an alpha-FR antibody labeled with antimouse-phycoerythrin have been used to label tumor cells, with a CD45-phycoerythrin-cyanine5 antibody used to exclude white blood cells from the analysis. The method was optimized using human carcinoma cell lines (JEG-3, IGROV-1, and KB cells). Calibrated beads were used to quantify the number of antibodies bound per cell. The triple antibody protocol successfully measured alpha-FR expression levels in cell lines spiked with blood. Tumor cells were obtained from ascites in 25 patients with relapsed ovarian cancer. In each case sufficient cells were harvested to identify an epithelial cell population to estimate the number of binding sites/cell. All the samples contained a single population of BerEP4, alpha-FR positive cells between 5x10(3) and 5x10(5) antibody binding sites/cell. The method can be used to determine the number of anti-alpha-FR antibodies bound per epithelial cell in ascites from patients with ovarian carcinoma. The results obtained were reproducible and the method could be applied to specimens that had been stored at -80 degrees C. Copyright (c) 2007 International Society for Analytical Cytology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712798     DOI: 10.1002/cyto.a.20456

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  10 in total

1.  Enrichment and ratiometric detection of circulating tumor cells using PSMA- and folate receptor-targeted magnetic and surface-enhanced Raman scattering nanoparticles.

Authors:  Pradyumna Kedarisetti; Vincent R Bouvet; Wei Shi; Cody N Bergman; Jennifer Dufour; Afshin Kashani Ilkhechi; Kevan L Bell; Robert J Paproski; John D Lewis; Frank R Wuest; Roger J Zemp
Journal:  Biomed Opt Express       Date:  2020-10-08       Impact factor: 3.732

Review 2.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

3.  Fluorescence Labeling of Circulating Tumor Cells with a Folate Receptor-Targeted Molecular Probe for Diffuse In Vivo Flow Cytometry.

Authors:  Roshani A Patil; Madduri Srinivasarao; Mansoor M Amiji; Philip S Low; Mark Niedre
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

Review 4.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

5.  Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.

Authors:  Christian Brand; Ahmad Sadique; Jacob L Houghton; Kishore Gangangari; Jose F Ponte; Jason S Lewis; Naga Vara Kishore Pillarsetty; Jason A Konner; Thomas Reiner
Journal:  EJNMMI Res       Date:  2018-08-28       Impact factor: 3.138

6.  Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts.

Authors:  Esben Christensen; Jonas R Henriksen; Jesper T Jørgensen; Yasmine Amitay; Hilary Shmeeda; Alberto A Gabizon; Andreas Kjær; Thomas L Andresen; Anders E Hansen
Journal:  Int J Nanomedicine       Date:  2018-11-19

7.  Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics.

Authors:  Shujun Dong; Ian Nessler; Anna Kopp; Baron Rubahamya; Greg M Thurber
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.988

8.  A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.

Authors:  Brian C Avanzino; Kirthana Prabhakar; Pranjali Dalvi; Sharon Hartstein; Hannes Kehm; Aarti Balasubramani; Andrew A Boudreau; Ben Buelow; Karen Chang; Laura M Davison; Suhasini Iyer; Vidyut Kalwit; Kristin Lewis Wilson; Harbani K Malik-Chaudhry; Will Pierson; Geovanni Pineda; Udaya S Rangaswamy; Sowmya Saiganesh; Ute Schellenberger; Harshad S Ugamraj; Rodolfovan D Yabut; Roland Buelow; Jocelyn Chapman; Nathan D Trinklein; Katherine E Harris
Journal:  Oncoimmunology       Date:  2022-08-20       Impact factor: 7.723

Review 9.  Targeting folate receptor alpha for cancer treatment.

Authors:  Anthony Cheung; Heather J Bax; Debra H Josephs; Kristina M Ilieva; Giulia Pellizzari; James Opzoomer; Jacinta Bloomfield; Matthew Fittall; Anita Grigoriadis; Mariangela Figini; Silvana Canevari; James F Spicer; Andrew N Tutt; Sophia N Karagiannis
Journal:  Oncotarget       Date:  2016-08-09

10.  Preventive effects of folic acid on Zika virus-associated poor pregnancy outcomes in immunocompromised mice.

Authors:  Yogy Simanjuntak; Hui-Ying Ko; Yi-Ling Lee; Guann-Yi Yu; Yi-Ling Lin
Journal:  PLoS Pathog       Date:  2020-05-11       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.